Progress in ovarian cancer: An overview and perspective

European Journal of Cancer, Supplement

Volumn 1, Issue 2, 2003, Pages 43-55

  Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Molecular targeting; Ovarian oncogenesis

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FENRETINIDE; GEMCITABINE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DESIGN; DRUG MEGADOSE; DRUG WITHDRAWAL; EARLY CANCER; EARLY DIAGNOSIS; FAMILIAL CANCER; FEBRILE NEUTROPENIA; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONCOGENE; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 2442417750     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00008-9     Document Type: Article

References (68)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer Statistics, 2001. CA Cancer J. Clin. 51:2001;15-36
2. Hensley M.L., Castiel M., Robson M.E. Screening for ovarian cancer. what we know, what we need to know Oncology. 14:2000;1601-1607
3. Edmondson R.J., Monaghan J.M. The epidemiology of ovarian cancer. Int. J. Gynecol. Cancer. 11:2001;423-429
4. Vessey M., Painter R. Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br. J. Cancer. 71:1995;1340-1342
5. Risch H.A., Howe G.R. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prevent. 4:1995;447-451
6. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 90:1998;1774-1786
7. Fathalla M. Incessant ovulation - a factor in ovarian neoplasia? Lancet. 2:1971;163
8. Godwin A., Testa J., Handel L., et al. Spontaneous transformation of rat ovarian surface epithelial cells implicates repeated ovulation in ovarian cancer etiology and is associated with clonal cytogenetic changes. J. Natl. Cancer Inst. 84:1992;592-601
9. Prowse A, Frolov A, Godwin AK. Genetics. In Steele GD, Phillips TL, Chabrer BA, eds. American Cancer Society of Clinical Oncology, Ovarian Cancer. Hamilton, Ontario, BC Decker Inc., 2003, 49-82.
10. Bellacosa A., de Feo D., Godwin A.K., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer. 64:1995;280-285
11. Berchuck A., Kamel A., Whitaker R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091
12. Eisenhauer E.A., Gore M., Neijt J.P. Ovarian cancer. should we be managing patients with good and bad prognostic factors in the same manner? Ann. Oncol. 10:1999;9-17
13. Bruening W., Giasson B.I., Klein-Szanto A.J., Lee V.M., Trojanowski J.Q., Godwin A.K. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 88:2000;2154-2163
14. Mazars R., Sinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 52:1992;918-923
15. Mazars R., Pujol P., Maudelonde T., Jeanteur P., Theillet C. p53 mutations in ovarian cancer. a late event? Oncogene. 6:1991;1685-1690
16. Sheng Z., Sun W., Smith E., Cohen C., Sheng Z., Xu X.X. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene. 19:2000;4847-4854
17. Capo-Chichi CD, Smith ER, Yang DH, et al. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformations, tumorigenicity, and metastasis. Cancer 2002, 95, 1802-1815.
18. Hough C.D., Sherman-Baust C.A., Pizer E.S., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60:2000;6281-6287
19. Ismail R.S., Baldwin R.L., Fang J., et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60:2000;6744-6749
20. Yu Y., Xu F., Peng H., Fang X., et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA. 96:1999;214-219
21. Abdollahi A., Roberts D., Godwin A.K., et al. Identification of a zinc-finger gene at 6q25. a chromosomal region implicated in development of many solid tumors Oncogene. 14:1997;1973-1979
22. Mok S.C., Chao J., Skates S., Wong K., et al. Prostasin, a potential serum marker for ovarian cancer. identification through microarray technology J. Natl. Cancer Inst. 93:2001;1458-1464
23. Boyd J., Rubin S.C. Hereditary ovarian cancer. molecular genetics and clinical implications Gynecol. Oncol. 64:1997;196-206
24. Blackwood M.A., Weber B.L. BRCA1 and BRCA2. from molecular genetics to clinical medicine J. Clin. Oncol. 16:1998;1969-1977
25. Merajver S.D., Pham T.M., Caduff R.F., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet. 9:1995;439-443
26. Collins F.S. BRCA1-lots of mutations, lots of dilemmas. N. Engl. J. Med. 334:1996;186-188
27. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. N. Engl. J. Med. 339:1998;424-428
28. Gynecologic Oncology Group Protocol #0190. An exploratory evaluation of fenretinide (4-HPR) as a chemopreventive agent for ovarian carcinoma. Study Chair: Mary B. Daly, MD, PhD.
29. Salazar H., Godwin A., Daly M., et al. Microscopic benign and invasive malignant neoplasms and a preneoplastic phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. 88:1996;1810-1820
30. Ozols R.F., Rubin S.C., Thomas G.M., Robboy S.J. Epithelial Ovarian Cancer. Hoskins W.J., Perez C.A., Young R.C. Principles and Practice of Gynecologic Oncology. 2000;981-1057 Lippincott Williams & Wilkins, Philadelphia
31. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer. a Gynecologic Oncology Group study Gynecol. Oncol. 47:1992;159-166
32. van der Burg M.E.L., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N. Engl. J. Med. 332:1995;629-634
33. Vergote I., DeWever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma. a retrospective analysis of 285 patients Gynecol. Oncol. 71:1998;431-436
34. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer. long-term survival Gynecol. Oncol. 72:1999;93-99
35. Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180
36. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322:1990;1021-1027
37. Vergote I., De Brabanter J., Fyles A., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 357:2001;176-182
38. Vergote I.B., Trimbos B.J., Guthrie D., et al. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. Proc. Am. Soc. Clin. Oncol. 20:2001;201a. (abstr 802)
39. Advanced Ovarian Cancer Trialists Group Chemotherapy in advanced ovarian cancer. an overview of randomised clinical trials Br. Med. J. 303:1991;884-893
40. Aabo K., Adams M., Adnitt P., et al. Chemotherapy in advanced ovarian cancer. four systematic meta-analyses of individual patients data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group Br. J. Cancer. 78:1998;1479-1487
41. Ovarian Cancer Meta-Analysis Project Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma. a meta-analysis J. Clin. Oncol. 9:1991;1668-1674
42. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barret R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy. a Gynecologic Oncology Group study J. Clin. Oncol. 12:1994;1748-1753
43. Piccart M.J., Gore M., ten Bokkel Huinink ?., et al. Docetaxel. an active new drug for treatment of advanced epithelial ovarian cancer J. Natl. Cancer Inst. 87:1995;676-681
44. McGuire W.P., Hoskins W.J., Brady M.R., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
45. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. three-year results J. Natl. Cancer Inst. 92:2000;699-708
46. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 18:2000;106-115
47. Colombo N on behalf of the ICON Collaborators Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin). the Third International Collaborative Ovarian Neoplasm study (ICON3) Proc. Am. Soc. Clin. Oncol. 19:2000;379a. (abstr 1500)
48. ICON collaborators ICON2. randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer Lancet. 352:1998;1571-1576
49. duBois A., Luenck H.J., Meier W., et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer. update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial Proc. Am. Soc. Clin. Oncol. 18:1999;356a. (abstr. 1374)
50. Neijt J.P., Engelholm S.A., Tuxen M.K., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18:2000;3084-3092
51. Ozols R.F., Bundy B.N., Fowler J., et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC). a Gynecologic Oncology Group trial (GOG 158) Proc. Am. Soc. Clin. Oncol. 18:1999;356a. (abstr 1373)
52. Bookman M.A., McGuire W.P., Kilpatrick D., et al. Carboplatin and paclitaxel in ovarian carcinoma. a phase I study of the Gynecologic Oncology Group J. Clin. Oncol. 14:1996;1895-1902
53. Scarfone G., Parazzini F., Sciatta C., et al. A multicenter randomized trial comparing two different doses of Taxol (T) plus a fixed dose of carboplatin (C) in advanced ovarian cancer (AOC). Proc. Am. Soc. Clin. Oncol. 20:2001;205a. (abstr 816)
54. Vasey P on behalf of the Scottish Gynaecologic Cancer Trials Group Preliminary results of the SCOTROC trial. a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC) Proc. Am. Soc. Clin. Oncol. 10:2001;202a. (abstr 804)
55. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma. an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19:2001;1001-1007
56. Stiff P.J., Veum-Stone J., Lazarus H.M., et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer. an autologous blood and marrow transplant registry report Ann. Intern. Med. 133:2000;504-515
57. Ledermann J.A., Herd R., Maraninchi D., et al. High dose chemotherapy in ovarian cancer. an analysis of the experience of the European Group for Blood and Marrow Transplant (EBMT) over 7 years Proc. Am. Soc. Clin. Oncol. 18:1999;. (abstr. 1391)
58. Markman M., Liu P.Y., Wilczynski S., et al. Pahse III randomized trial of I2 versus three months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. J. Clin. Oncol. 21:2003;2460-2465
59. Cure H., Battista C., Guastalla J., et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC). preliminary results of a GINECO/FNCLCC/SFGM-TC study Proc. Am. Soc. Clin. Oncol. 20:2001;204a. (abstr 815)
60. Berek J., Ehlen T., Gordon A., et al. Interim analysis of a double blind study of Ovarex™ mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;210a. (abstr 837)
61. Herrin V.E., Thigpen T. Recent developments in the treatment of recurrent ovarian carcinoma. Adv. Oncol. 16:2000;21-29
62. Ozols R.F. Treatment of recurrent ovarian cancer. increasing options - "Recurrent" results J. Clin. Oncol. 15:1997;2177-2180
63. Hansen S.W., Anderson H., Boman K., et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc. Am. Soc. Clin. Oncol. 18:1999;357a. (abstr 1379)
64. Hoskins P., Eisenhauer E., Vergote I., et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer. a National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 18:2000;4038-4044
65. DuBois A., Weber B., Pfisterer J., et al. Epirubicin/paclitaxel/ carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of an AGO-GINECO Intergroup Phase III trial. Proc. Am. Soc. Clin. Oncol. 20:2001;202a. (abstr. 805)
66. Gynecologic Oncology Group Protocol #182. A phase III randomized trial of paclitaxel and carboplatin versus triplet or sequential doublet combinations in patients with epithelial ovarian or primary peritoneal carcinoma. Study Chair: MA Bookman.
67. Finkler N., Gordon A., Crozier M., et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;208a. (abstr 831)
68. Gynecologic Oncology Group Protocol #170. A phase II trial of ZD1839 (Iressa) (NSC#715055) in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma. Study Chair: R. Schilder.